Literature DB >> 17004233

The putative use of alpha-1-acid glycoprotein as a non-invasive marker of fibrosis.

Paul Mooney1, Peter Hayes, Kevin Smith.   

Abstract

The acute phase response to injury or infection results in alterations in the expression of the plasma proteins produced by the liver. Many of these biomolecules are glycosylated with oligosaccharide chains covalently attached to the polypeptide backbone and the extent and composition of this glycosylation can be altered in a disease-dependent manner. Of particular interest is the observation that the acute phase glycoprotein, alpha-1-acid glycoprotein (AGP) has altered glycosylation in several physiological and pathological conditions. It is posited that changes induced in liver diseases may reflect disease severity and may therefore act as a non-invasive marker of fibrosis. This study has investigated the glycosylation of AGP in the plasma of people with varying degrees of cirrhosis and fibrosis. Hyperfucosylation was observed in all disease samples in comparison to normal plasma and was significantly increased in cirrhosis. Both sialic acid and N-acetylgalactosamine (GalNAc) were negatively associated with fibrosis. Two samples were found to express GalNAc, which as a constituent of the glycosylation of serum proteins is rare. In conclusion, fucose, sialic acid and other aspects of the glycosylation of AGP are influenced by the degree of fibrosis and as such may prove a valuable prognostic indicator of the development of cirrhosis. Copyright (c) 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17004233     DOI: 10.1002/bmc.704

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  6 in total

Review 1.  Characterization of isomeric glycan structures by LC-MS/MS.

Authors:  Lucas Veillon; Yifan Huang; Wenjing Peng; Xue Dong; Byeong Gwan Cho; Yehia Mechref
Journal:  Electrophoresis       Date:  2017-05-17       Impact factor: 3.535

2.  Fucosylation of serum alpha1-acid glycoprotein in rheumatoid arthritis patients treated with infliximab.

Authors:  Anna Olewicz-Gawlik; Izabela Korczowska-Łacka; Jan K Łacki; Kamilla Klama; Paweł Hrycaj
Journal:  Clin Rheumatol       Date:  2007-02-20       Impact factor: 2.980

3.  Serum protein biomarkers screening in HCC patients with liver cirrhosis by ICAT-LC-MS/MS.

Authors:  Xiaonan Kang; Lu Sun; Kun Guo; Hong Shu; Jun Yao; Xue Qin; Yinkun Liu
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-04       Impact factor: 4.553

4.  Enhanced expression of alpha1-acid glycoprotein and fucosylation in hepatitis B patients provides an insight into pathogenesis.

Authors:  Gautam Mondal; Urmimala Chatterjee; Hasi R Das; Bishnu P Chatterjee
Journal:  Glycoconj J       Date:  2009-12       Impact factor: 2.916

5.  Alpha-1-acid glycoprotein as potential biomarker for alpha-fetoprotein-low hepatocellular carcinoma.

Authors:  Indra Bachtiar; Valentine Kheng; Gunawan A Wibowo; Rino A Gani; Irsan Hasan; Andri Sanityoso; Unggul Budhihusodo; Syafruddin Ar Lelosutan; Ruswhandi Martamala; Wenny A Achwan; Soewignyo Soemoharjo; Ali Sulaiman; Laurentius A Lesmana; Susan Tai
Journal:  BMC Res Notes       Date:  2010-11-23

6.  Orosomucoid in liver diseases.

Authors:  Gulsum Ozlem Elpek
Journal:  World J Gastroenterol       Date:  2021-12-07       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.